Abstract:Objective: To investigate the roles of TNF-alpha, GSK-3 beta and RANKL in the occurrence and development of diabetic osteoporosis. Methods: Diabetic rat model was established; tissue section technology was used to observe the situation of osteoporosis in diabetic rats; rat serum levels of OC, RANKL, GSK-3 beta, P38mapk, TNF-alpha and INS were detected by Elisa assay; osteoblasts and osteoclasts were primarily cultured and identified by immunohistochemistry and tartrate-resistant acid phosphatase (TRAP) staining respectively. The effects of GSK-3 beta inhibitors, lithium chloride, TNF-alpha antagonists and RANKL antagonists on the proliferation of osteoblasts and osteoclasts were evaluated; quantitative PCR was used to assess the effects of GSK-3 beta inhibitors, lithium chloride, on TNF-alpha and RANKL gene expression in osteoblasts and osteoclasts, and the effects of TNF-alpha and RANKL antagonists on GSK-3 beta gene expression in osteoblasts and osteoclasts. Results: Diabetic rat model was successfully established; osteoblasts and osteoclasts were successfully isolated and cultured. Elisa experiments showed that in diabetic model group, the levels of RANKL, GSK-3 beta, P38mapk and TNF-alpha were significantly increased, while the levels of osteocalcin (OC) and insulin (INS) were significantly reduced; MTT results showed that osteoclast proliferation in GSK-3 beta inhibitor and lithium chloride groups were weaker than the untreated group, while osteoclast proliferation in TNF-alpha antagonist group and RANKL antagonist Group was very close to the untreated group. Osteoblast proliferation in GSK-3 beta inhibitor and lithium chloride groups were weaker than the untreated group, while osteoblast proliferation in TNF-alpha antagonist group and RANKL antagonist group was higher than the untreated group. In all of the corresponding groups, cell proliferation in the diabetic group was stronger than the untreated group. In GSK-3 beta inhibitor and lithium oxide groups, TNF-alpha and RANKL gene expression levels were elevated, but TNF-alpha and RANKL gene expression levels in the diabetic group were slightly lower than the control group. GSK-3 beta gene expression level in TNF-alpha antagonist group and RANKL antagonist group was reduced; GSK-3 beta gene expression level in diabetic group was lower than the control group. Conclusion: In diabetic rats, TNF-alpha, GSK-3 beta and RANKL levels were elevated; GSK-3 beta could promote the proliferation of osteoblasts and osteoclasts, and inhibit the expression of TNF-alpha and RANKL; TNF-alpha and RANKL can suppress the proliferation of osteoblasts while had little effect on osteoclast proliferation; they also can promote the GSK-3 beta gene expression; interactions between the three broke the balance between osteoblasts and osteoclasts, leading to osteoporosis.

Roles of osteoprotegerin in endocrine and metabolic disorders through receptor activator of nuclear factor kappa-B ligand/receptor activator of nuclear factor kappa-B signaling

Role of OPG/RANKL/RANK system during alveolar bone resorption and remodeling

The Role of Osteoprotegerin and Its Ligands in Vascular Function

The Role of Osteoprotegerin in Vascular Calcification and Bone Metabolism: The Basis for Developing New Therapeutics

Receptor Activator of Nuclear Factor-Κb Ligand (rankl)/rank/osteoprotegerin System in Bone and Other Tissues (Review)

The Role of the Receptor Activator of Nuclear Factor Kappa-B Ligand/Osteoprotegerin Ratio in Vascular Diseases: A Therapeutic Approach

Research Progress of RANK/RANKL/OPG Signaling Pathway

Receptor Activator Of Nuclear Factor-Kappa B Ligand (Rankl)/Rank/Osteoprotegerin System In Bone And Other Tissues

Research progress of osteoprotegerin in cardiovascular disease

The RANK/RANKL/OPG system and tumor bone metastasis: Potential mechanisms and therapeutic strategies

Application of osteoprotegerin in periodontal tissue regeneration

Roles Of Tnf-Alpha, Gsk-3 Beta And Rankl In The Occurrence And Development Of Diabetic Osteoporosis

Stress Sensitive Signal Pathway Osteoprotegerin/Receptor Activator of Nuclear Factor-κB ligand/Receptor Activator of Nuclear Fac-tor-κB and Osteoporosis (review)

The RAGE signaling in osteoporosis

Research progress and application of OPG/RANK/RANKL signaling pathway in osteoporosis

Targeting the RANKL/RANK/OPG Axis for Cancer Therapy

Roles of TNF-α, GSK-3β and RANKL in the Occurrence and Development of Diabetic Osteoporosis.

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives

Receptor activator of nuclear factor-κB ligand-mediated osteoclastogenesis signaling pathway and related therapeutic natural compounds

Receptor activator of nuclear factor-B ligand-mediated osteoclastogenesis signaling pathway and related therapeutic natural compounds

Osteoprotegerin Mediates Adipogenesis in Obesity